[A patient with persistent arrythmias and eczema].
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
(1) Cisapride prolongs the QT interval and can cause torsades de pointes and ventricular tachycardia. (2) Cases of cardiac arrhythmia and death have occurred, even in the absence of underlying factors such as high doses and interactions with enzyme-inhibiting drugs (especially macrolide antibiotics, HIV protease inhibitors and antifungal imidazoles). (3) Cisapride was withdrawn from the market in the United States on 14 July 2000 and in Canada on 7 August 2000. We recommend that this measure should be applied worldwide.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Myocardial taurine level was found to be greater in the rat than in the guinea-pig. Taurine inhibited the development of arrhythmias caused by the i.v. infusion of ouabain in the rat. When ouabain induced arrhythmias, the myocardial taurine level decreased. Both effects were blocked by pretreatment of propranolol. The uptake of taurine into the heart did not necessarily result in the reversal of the PR interval prolonged by ouabain. The protecting effect of taurine against ouabain toxicity was not dependent upon the change in myocardial total ATPase activity.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.